Log In
BCIQ
Print this Print this
 

CD19 CAR T cells

  Manage Alerts
Collapse Summary General Information
Company Uppsala University
DescriptionThird-generation autologous chimeric antigen receptor (CAR) T cells targeting CD19
Molecular Target CD19
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationB cell lymphoma
Indication DetailsTreat relapsed or refractory CD19-positive B cell malignancies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today